Clinical Study
Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
Table 1
Patients’ characteristics for bortezomib retreatment.
| | Characteristic | Patients, (%) |
| | Total number of patients | 30 | | Gender, male | 10 (33.3) | | Median age at start of bortezomib retreatment, years (range) | 67 (51–81) | | Age ≥65 years, (%) | 18 (60) | | Median time in months from diagnosis to bortezomib retreatment (range) | 43.6 (16.9–249.6) | | Median time in months from initial bortezomib treatment to retreatment (range) | 12.9 (6.7–63.5) | | Paraprotein type at bortezomib retreatment | | | IgG | 17 (56.7) | | IgA | 7 (23.3) | | Light-chain disease | 6 (20.0) | | Durie-Salmon stage at diagnosis, (%) | = 28 | | I | 4 (14.3) | | II | 6 (21.4) | | III | 18 (64.3) | | Creatinine ≥2 mg/dL at diagnosis | 4 (13.3) | | ISS stage at diagnosis (%) | = 28 | | I | 12 (42.9) | | II | 6 (21.4) | | III | 10 (35.7) | | ISS stage at the study enrollment (%) | = 25 | | I | 14 (56.0) | | II | 5 (20.0) | | III | 6 (24.0) | | Prior treatments, median (range) | 2 (2–5) | | Prior line of therapy, | | | 2 | 17 (57) | | 3 | 6 (20) | | 4 | 4 (13) | | 5 | 3 (10) | | Prior autologous stem cell transplantation, (%) | 15 (50.0) | | Prior thalidomide exposure | 28 (93.3) | | Prior bortezomib combination therapy | | | Vel-CD | 10 (33) | | Vel-CTD | 20 (67) | | Combination chemotherapy during bortezomib retreatment | | | Vel-CD | 7 (33.3) | | Vel-CTD | 21 (70) | | Velcade, dexamethasone, panobinostat | 2 (6.7) |
|
|
ISS: International Staging System; Vel-CD: bortezomib, cyclophosphamide, and dexamethasone; Vel-CTD: bortezomib, cyclophosphamide, thalidomide, and dexamethasone; FISH: fluorescence in situ hybridization; CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease; PD: progressive disease.
|
